Caribou presents clinical data from CB-010 ANTLER Phase 1 trial

Caribou Biosciences presented updated clinical data from the ongoing ANTLER Phase 1 trial that indicates a single dose of CB-010, a readily available, off-the-shelf anti-CD19 CAR-T cell therapy with a PD-1 knockout, has the potential to rival the safety, efficacy, and durability of approved autologous CAR-T cell therapies. The clinical results were presented during a poster presentation at the 2024 American Society of Clinical Oncology Annual Meeting. In ANTLER, three dose levels of CB-010 were evaluated in a total of 46 patients. In dose escalation, 16 patients with multiple subtypes of aggressive relapsed or refractory B cell non-Hodgkin lymphoma were enrolled, and in dose expansion, 30 patients with second-line large B cell lymphoma were enrolled. As of an April 1, 2024 data cutoff date, results demonstrated: CB-010 was generally well tolerated. No Grade 3 or higher cytokine release syndrome and no graft-versus-host disease was observed. A retrospective analysis of all patient data demonstrated that patients who received a dose of CB-010 manufactured from a donor with greater than or equal to4 matching HLA alleles showed improved progression free survival. Results from patients who received partially HLA matched CB-010 include: Median PFS of 14.4 months was observed in patients treated with CB-010 with greater than or equal to4 HLA matches, compared to 2.8 months for patients treated with CB-010 with less than or equal to3 HLA matches. In patients with LBCL who received CB-010 with greater than or equal to 4 HLA matches, median PFS has not been reached. Translational data on CB-010: Pharmacokinetic data showed that higher numbers of matched HLA alleles between the CB-010 donor and recipient patient correlated with increased CAR-T cell expansion and persistence compared to lower numbers of matched HLA alleles. Pharmacodynamic data showed that a single dose of CB-010 resulted in extended B cell aplasia and a rapid recovery of the patient’s endogenous T and NK cells. Based on the overall safety, efficacy, and translational data analyzed, 80×106 CAR-T cells was selected as the recommended Phase 2 dose for CB-010.